PLASMID DNA MANUFACTURING MARKET ANALYSIS

Market Challenges And Opportunities

Global Plasmid DNA Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to World Health Organization (WHO) as of October 10, 2022, 44,614,437 people are affected worldwide.

 The key players operating in the market are focusing on development of DNA vaccines for the treatment of Covid -19. For instance, in May 2020, AGC Biologics, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, partnered with Takara Bio, the biomedical business unit of Takara Shuzo Co., Ltd., to develop vaccine for COVID-19. As a result of this partnership, AGC Biologics is manufacturing the plasmid DNA intermediate vaccine for treatment of COVID-19 with Takara Bio.

Global Plasmid DNA Manufacturing Market: Restraint

The high cost of gene therapies is adversely affecting the market growth. For instance, according to an article published by PubMed in May 2021, an upfront price of US$ 2.125 million, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy, a rare neuromuscular disorder that is usually fatal by 2 years of age if untreated, has been called the "most expensive drug ever”. Therefore, it is essential to lower the prices quoted by companies in order to increase the market reach.